Vertex gets regulatory nod

Vertex Pharmaceuticals Inc has received a new approval from the US Food and Drug Administration for its cystic fibrosis treatment Kalydeco (ivacaftor) that triples the number of rare gene mutations that the drug can treat to 33 from 10.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States